Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Inventory (2016 - 2025)

Ocular Therapeutix (OCUL) has 12 years of Inventory data on record, last reported at $3.6 million in Q4 2025.

  • For Q4 2025, Inventory rose 17.24% year-over-year to $3.6 million; the TTM value through Dec 2025 reached $3.6 million, up 17.24%, while the annual FY2025 figure was $3.6 million, 17.24% up from the prior year.
  • Inventory reached $3.6 million in Q4 2025 per OCUL's latest filing, up from $3.5 million in the prior quarter.
  • Across five years, Inventory topped out at $3.6 million in Q4 2025 and bottomed at $1.1 million in Q2 2021.
  • Average Inventory over 5 years is $2.2 million, with a median of $2.3 million recorded in 2023.
  • Peak YoY movement for Inventory: increased 1.45% in 2021, then soared 66.86% in 2023.
  • A 5-year view of Inventory shows it stood at $1.2 million in 2021, then soared by 57.92% to $2.0 million in 2022, then rose by 16.77% to $2.3 million in 2023, then soared by 31.89% to $3.0 million in 2024, then grew by 17.24% to $3.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $3.6 million in Q4 2025, $3.5 million in Q3 2025, and $3.0 million in Q2 2025.